MA53272A - Procédé de préparation d'une formulation pharmaceutique d'anticorps - Google Patents

Procédé de préparation d'une formulation pharmaceutique d'anticorps

Info

Publication number
MA53272A
MA53272A MA053272A MA53272A MA53272A MA 53272 A MA53272 A MA 53272A MA 053272 A MA053272 A MA 053272A MA 53272 A MA53272 A MA 53272A MA 53272 A MA53272 A MA 53272A
Authority
MA
Morocco
Prior art keywords
preparing
antibody formulation
pharmaceutical antibody
pharmaceutical
formulation
Prior art date
Application number
MA053272A
Other languages
English (en)
Inventor
Bryan Dransart
Ashutosh Sharma
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53272A publication Critical patent/MA53272A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA053272A 2018-08-10 2019-08-09 Procédé de préparation d'une formulation pharmaceutique d'anticorps MA53272A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862717357P 2018-08-10 2018-08-10

Publications (1)

Publication Number Publication Date
MA53272A true MA53272A (fr) 2021-11-17

Family

ID=67734839

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053272A MA53272A (fr) 2018-08-10 2019-08-09 Procédé de préparation d'une formulation pharmaceutique d'anticorps

Country Status (14)

Country Link
US (1) US20210308265A1 (fr)
EP (1) EP3833327A1 (fr)
JP (2) JP7425041B2 (fr)
KR (1) KR20210043607A (fr)
CN (1) CN112702991A (fr)
AU (1) AU2019316575A1 (fr)
BR (1) BR112021002506A2 (fr)
CA (1) CA3108693A1 (fr)
EA (1) EA202190482A1 (fr)
IL (1) IL280642A (fr)
MA (1) MA53272A (fr)
MX (1) MX2021001554A (fr)
SG (1) SG11202100952QA (fr)
WO (1) WO2020033788A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1391707A (en) 1918-08-15 1921-09-27 Viviano Philip Automatic change-speed transmission
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
DK1133558T4 (en) 1998-11-27 2016-05-17 Ucb Sa Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4688802B2 (ja) 2003-06-16 2011-05-25 セルテック アール アンド ディー， インコーポレイテッド 骨の鉱化作用を増大させるためのスクレロスチンに特異的な抗体および方法
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1962907A2 (fr) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Formulations de proteines a viscosite reduite et leurs utilisations
EP2114435A1 (fr) 2007-02-02 2009-11-11 Novartis AG Modulateurs de partenaires de liaison de la sclérostine pour traiter des troubles liés aux os
EP2131860B1 (fr) 2007-03-20 2013-12-18 Eli Lilly & Company Anticorps antisclérostine
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
DK2567709T3 (en) 2007-11-02 2018-03-12 Novartis Ag Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010100179A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
WO2010130830A2 (fr) 2009-05-15 2010-11-18 Ablynx N.V. Séquences d'acides aminés dirigées contre la sclérostine et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies des os
SG10201912670XA (en) * 2010-05-14 2020-02-27 Amgen Inc High concentration antibody formulations
EP3240571A4 (fr) * 2014-12-31 2018-06-13 NovelMed Therapeutics, Inc. Formulation d'anticorps thérapeutiques aglycosylés
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation

Also Published As

Publication number Publication date
CN112702991A (zh) 2021-04-23
MX2021001554A (es) 2021-04-13
CA3108693A1 (fr) 2020-02-13
AU2019316575A1 (en) 2021-03-04
EA202190482A1 (ru) 2021-05-25
SG11202100952QA (en) 2021-02-25
IL280642A (en) 2021-03-25
JP7425041B2 (ja) 2024-01-30
JP2021534117A (ja) 2021-12-09
BR112021002506A2 (pt) 2021-07-27
JP2024045250A (ja) 2024-04-02
EP3833327A1 (fr) 2021-06-16
KR20210043607A (ko) 2021-04-21
US20210308265A1 (en) 2021-10-07
WO2020033788A1 (fr) 2020-02-13

Similar Documents

Publication Publication Date Title
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
MA48763A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
MA53920A (fr) Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
MA50239A (fr) Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique
MA45562A (fr) Préparation pharmaceutique liquide stable
MA52154A (fr) Composition pharmaceutique pour l'anémie
MA45450B1 (fr) Formulations d'anticorps anti-cd19
MA44209A (fr) Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate
MA55033A (fr) Formulation d'anticorps thérapeutique
MA37317B1 (fr) Formulation d'anticorps il-17
MA45768A (fr) Procédé pour la préparation de compositions d'immunoglobulines
MA53927A (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MA53272A (fr) Procédé de préparation d'une formulation pharmaceutique d'anticorps
MA46100A (fr) Composition pharmaceutique comprenant de la rosuvastatine et de l'ézétimibe et son procédé de préparation
MA52704A (fr) Préparation pharmaceutique
MA53466A (fr) Formulation stable d'anticorps anti-osmr
MA54701A (fr) Procédé de préparation de nutriments à partir d'insectes
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
MA55559A (fr) Procédé d'administration d'un anticorps anti-ifn-alpha/-oméga
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
FR3081298B1 (fr) Dispositif de preparation d'une composition cosmetique, jeu de capsules et procede de preparation associes
MA45794A (fr) Système de marqueur pour confirmer l'exactitude de compositions et de formulations agrochimiques
FR2927539B1 (fr) Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
MA52587A (fr) Composés d'azabenzimidazole et produit pharmaceutique